PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A

Autor:	Maria Elisa Mancuso, Monika Maas Enriquez, Tina T. Biss, Despina Tseneklidou-Stoeter, MacGregor Steele, Maria Wang, Krista Fischer, Gili Kenet, Sanjay P Ahuja
Rok vydání:	2021
Předmět:	Male FVIII damoctocog alfa pegol Pediatrics medicine.medical_specialty Haemophilia A haemophilia A 030204 cardiovascular system & hematology Hemophilia A Haemophilia Recombinant factor viii Polyethylene Glycols 03 medical and health sciences 0302 clinical medicine children medicine Humans adolescents Child Clinical Haemophilia Genetics (clinical) Paediatric patients Factor VIII business.industry Extension study Infant Newborn Original Articles Hematology General Medicine medicine.disease Treatment Outcome polyethylene glycol Original Article Severe haemophilia A prophylaxis Long term safety business Bay 030215 immunology
Zdroj:	Haemophilia
ISSN:	1365-2516 1351-8216 0177-5618
Popis:	Introduction BAY 94‐9027 (damoctocog alfa pegol; an extended half‐life PEGylated recombinant factor VIII [FVIII]) demonstrated efficacy and safety in previously treated paediatric patients (PTPs) aged
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e9eed4c3a7d7bf5b4093b2ac5e3ec6c https://doi.org/10.1111/hae.14294 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.